Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Delta Hepatitis Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced eight abstracts highlighting its chronic hepatitis B (CHB) and chronic hepatitis D (CHD) New Data from Clinical Program Accepted for Presentation at American Association for the Study of Liver Diseases (AASLD) Liver Meeting^®, taking place November 10-14, 2023 in Boston, Massachusetts. These include seven poster presentations, one of which is a new poster, and one new oral presentation.

“Our ongoing findings underscore the tremendous progress we are making in meeting the needs of the millions of people living with chronic hepatitis B and chronic hepatitis D,” said Dr. Phil Pang, Vir executive vice president and chief executive officer and medical officer. Interim Research Director. “We are eager to provide additional data from multiple ongoing trials at AASLD, particularly data from two recent reports regarding the potential clinical impact VIR-3434 and VIR-2218 may have in patients with CHB and CHD.”

More details about the latest posters and oral presentations will be shared on November 10, 2023.

The story continues

About chronic hepatitis B
Chronic hepatitis B (CHB) infection remains an urgent global public health challenge with high morbidity and mortality. Approximately 300 million people worldwide suffer from chronic hepatitis B, and approximately 900,000 people die from related complications every year. These patients are significantly underserved by existing therapies with low functional cure rates, lifelong daily treatment, and/or poor tolerability. Vir is committed to achieving functional cures for the millions of people living with chronic hepatitis B around the world through its broad and differentiated product portfolio.

About chronic hepatitis D
Chronic hepatitis D (CHD) infection is concurrent or superinfected with chronic hepatitis B. An estimated 12 million people worldwide are infected with CHD, accounting for approximately 5% of those infected with CHB. CHB-CHD co-infection is considered the most severe form of chronic viral hepatitis because it leads to more rapid progression to hepatocellular carcinoma and liver-related death.

About VIR-2218
VIR-2218 (BRII-835) is an investigational subcutaneously administered hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate an immune response and protect against hepatitis B virus and hepatitis delta virus Has direct antiviral activity. It is the first siRNA in the clinic to employ enhanced stability chemical enhancement (ESC+) technology to enhance stability and minimize off-target activity, which may result in an increased therapeutic index. VIR-2218 is the first asset from the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

About VIR-3434
VIR-3434 (BRII-877) is an investigational, subcutaneous antibody designed to block the entry of hepatitis B and D viruses into liver cells and reduce levels of virions and subviral particles in the blood. VIR-3434 combines Xencor’s Xtend™ and other Fc technologies and is engineered as a T-cell vaccine against hepatitis B virus and hepatitis delta virus with an extended half-life. VIR-3434 was identified using Vir’s proprietary monoclonal antibody discovery platform.

About Vir Biotechnology
Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious diseases. Vir has assembled two technology platforms designed to stimulate and enhance the immune system by leveraging key observations of natural immune processes. Its current clinical development pipeline includes product candidates targeting hepatitis B and D viruses, influenza A and B, human immunodeficiency virus and COVID-19. Vir is developing multiple preclinical drug candidates, including candidates targeting RSV/MPV and HPV. Vir frequently posts information on its website that may be important to investors.

forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “goal,” “expect,” “anticipate,” “hopefully” and similar expressions (as well as references to future events, conditions or (other words or expressions of context) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategies and plans, potential clinical effects of VIR-3434 and VIR-2218, statements of potential benefits, safety and efficacy of VIR-3434 and VIR-2218, from Vir’s multiple ongoing trials evaluating VIR-3434 and VIR-2218 data, Vir’s plans and expectations for its HBV and HDV product portfolio, and the risks and uncertainties associated with drug development and commercialization. Many factors could cause differences between current expectations and actual results, including unexpected safety or effectiveness data or results observed during clinical trials or data readouts; the occurrence of adverse safety events; the risk of unexpected costs, delays or other unexpected obstacles; difficulties in working with other companies; the success of Vir’s competitors in developing and or commercializing alternative product candidates; changes in anticipated or existing competition; delays or interruptions in Vir’s operations or clinical trials due to the COVID-19 pandemic, geopolitical changes (including the war in Ukraine) or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involves a high degree of risk, and only a small number of research and development projects lead to commercialization of products. The results of early clinical trials may not represent the full results or the results of later or larger clinical trials, and cannot Ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented. Discussions in Vir’s filings with the Securities and Exchange Commission that could cause actual results to differ from those expressed or implied by the forward-looking statements in this press release are other factors that vary, including in the section titled “Risk Factors” therein. Except as required by law, Vir disclaims any obligation to update any forward-looking statements contained herein to reflect changes in expectations, even if new information becomes available.

CONTACT: Contacts: Media Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1-314-368-5189 Investors Sasha Damouni Ellis Executive Vice President, Chief Corporate Affairs Officer sdamouni@vir.bio